Showing 2801-2810 of 4063 results for "".
- Bausch + Lomb Introduces 23-Gauge Bi-Blade Dual Port Vitrectomy Cutter for the Stellaris Elite Vision Enhancement Systemhttps://modernod.com/news/bausch-lomb-introduces-23-gauge-bi-blade-dual-port-vitrectomy-cutter-for-the-stellaris-elite-vision-enhancement-system/2476752/Bausch + Lomb announced the introduction of the 23-gauge Bi-Blade dual port vitrectomy cutter for the Stellaris Elite vision enhancement system. The new probe joins the available 25- and 27-gauge Bi-Blade cutters as options in the Bi-Blade portfolio. All Bi-Blade cutters double effective cut rate
- American Academy of Optometry Announces 2019 Award Recipientshttps://modernod.com/news/american-academy-of-optometry-announces-2019-award-recipients/2476738/The American Academy of Optometry announced its 2019 award recipients, recognizing distinguished individuals who have made important contributions to advancing the profession of optometry: Raymond A. Applegate,
- Trefoil Therapeutics Raises $28 Million Series A to Advance Engineered FGF-1 for the Treatment of Corneal Diseaseshttps://modernod.com/news/trefoil-therapeutics-raises-28-million-series-a-to-advance-engineered-fgf-1-for-the-treatment-of-corneal-diseases/2476735/Trefoil Therapeutics announced it raised $28 million in an oversubscribed Series A financing. The company is developing novel engineered fibroblast growth factor-1 proteins (eFGF-1) as a regenerative pharmacologic therapy to treat serious corneal endothelial diseases and epithelial disorders.
- BioTime Initiates Dosing in Phase 1/2a Clinical Study of OpRegen for Treatment of Dry AMDhttps://modernod.com/news/biotime-initiates-dosing-in-phase-1-2a-clinical-study-of-opregen-for-treatment-of-dry-amd/2476722/BioTime announced that it has dosed its first patient with the Orbit Subretinal Delivery System (Orbit SDS) as well as with a new thaw-and-inject formulation of OpRegen, the company’s retinal pigment epithelium (RPE) transplant therapy, in its ongoing phase 1/2a clinical study for the treatment o
- iSTAR Medical’s MINIject Shows Consistent Results at 18-Month Follow-Up in First-in-Human Trial (STAR-I)https://modernod.com/news/istar-medicals-miniject-shows-consistent-results-at-18-month-follow-up-in-first-in-human-trial-star-i/2476718/iSTAR Medical SA announced consistent 18-month results of the first-in-human, micro-invasive glaucoma surgery (MIGS) STAR-I trial for the MINIject device in a standalone setting. These results confirm the stability and sustained performance of MINIject beyond the first year, according to a compan
- NuSight Medical Announces Issuance of U.S. Patent Covering the NuLids System for Treating Dry Eye Diseasehttps://modernod.com/news/nusight-medical-announces-issuance-of-u-s-patent-covering-the-nulids-system-for-treating-dry-eye-disease/2476697/NuSight Medical, a medical device company focused on the doctor directed, at-home treatment of dry eye disease, announced that the U.S. Patent Office has issued Patent No. 10,314,763, which is directed to methods related to the treatment of dry eye disease. U.S. Patent No. 10,314,763 cover
- Alcon’s iLUX MGD Treatment System Wins Top Honor in 2019 Medical Design Excellence Awards (MDEA)https://modernod.com/news/alcons-ilux-mgd-treatment-system-wins-top-honor-in-2019-medical-design-excellence-awards-mdea/2476678/Alcon was selected as a Gold winner for its personalized iLUX MGD Treatment System at the 2019 Medical Design Excellence Awards (MDEA). The award was given in the “Nonsurgical Hospital Supplies and Equipment” category during an event held on June 11 in New York City. Products w
- CooperVision Showcases Latest Research in Series of Poster Sessions at Optometry’s Meeting 2019https://modernod.com/news/coopervision-showcases-latest-research-in-series-of-poster-sessions-at-optometrys-meeting-2019/2476676/As part of its commitment to the continuous advancement of contact lens study and support, CooperVision will share the results of new research in a series of four poster sessions at Optometry’s Meeting 2019 in St. Louis. The posters examine the performance of CooperVision clariti 1 day multifocal
- Alcon Showcases News Contact Lens Innovations and the iLUX System at the 2019 Optometry’s Meetinghttps://modernod.com/news/alcon-showcases-news-contact-lens-innovations-and-the-ilux-system-at-the-2019-optometrys-meeting/2476673/Alcon will launch Dailies Colors contact lenses at the 2019 Optometry’s Meeting, as well as give attendees a preview of PRECISION1 contact lenses coming soon to the US. These innovations, together with updates on the iLUX MGD Treatment System, new clinical data and practice insights, will be feat
- Ribomic Announces Positive Topline Results from the Phase 1/2a Clinical Trial of RBM-007 (SUSHI Study) in Subjects with Wet AMDhttps://modernod.com/news/ribomic-announces-positive-topline-results-from-the-phase-1-2a-clinical-trial-of-rbm-007-sushi-study-in-subjects-with-wet-amd/2476656/Ribomic announced positive topline results from its SUSHI study, a phase 1/2a single ascending dose clinical study of RBM-007, anti-FGF2 aptamer, in nine subjects with wet age-related macular degeneration (AMD). The SUSHI study achiev